News

Divya Srikumaran, MD, assistant professor of Ophthalmology at the Wilmer Eye Institute (Johns Hopkins University), discusses the results of a study published in the American Journalism of Ophthalmology regarding the growth and shift of the physician assistant profession into specialty care as well as the more valuable role PAs are taking in providing healthcare.

Pandemic highlights need for longer-lasting agents to reduce treatment burden in evolving field.

Large randomized trial compares efficacy and safety of multiple regimens

A vehicle-controlled phase 2 study investigating once- and twice-daily administration of a novel, preservative-free topical formulation of dexamethasone as treatment for pain and inflammation after cataract surgery met its primary endpoints.

Tim McCall, PhD, associate director, Surveys & Analysis, American Academy of PAs, discusses a study published in the American Journal of Ophthalmology exploring the expanding role of assistant physicians into specialty care and ophthalmology practice.

Susan Coultas, PhD, and Preeya Gupta, MD, share their hopes for continued innovation in the ophthalmic space — including dry eye and retina — as well as the importance of the clinical research process.

Pandemic is disrupting clinical facilities, putting individuals’ ocular health at risk

Michael X. Repka, MD, vice chair of clinical practice at Wilmer Eye Institute (Johns Hopkins University) speaks on the institution's latest protocol changes allowing for the resumption of elective surgery as well as the adaptations clinicians have had to make in order to ensure the continuation of clinical practice at Wilmer Eye Institute.

Ophthalmologists share their outlook for the current state and future of the ophthalmic profession, how coronavirus pandemic has altered the profession as well as how —now, more than ever — patient care remains a number one priority for ophthalmologists.

The use of a human monoclonal antibody (Narsoplimab, Omeros) to treat acute respiratory distress syndrome (ARDS) associated with COVID-19 resulted in recovery and survival of the affected patients.

Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.

Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.

This action will result in 2 separate companies,

Intravitreal injection offers safety, efficacy, and improved vision in patients

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

Researchers must weigh emotional, financial, and reputational considerations

ASRS 2020 coverage: Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

ASRS 2020 coverage: The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD,on behalf of the DRCR Retina Network.

Trabeculectomy may offer better results with more severe glaucoma

ASRS 2020 coverage: Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting. Faricimab is a bispecific antibody that simultaneously inhibits angiopoietin-2 and vascular endothelial growth factor A.

Technology is off to a good start, but improvements still needed

ASRS 2020 coverage: An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

ASRS 2020 coverage: Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.